Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors

Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors Strengthening Board of Directors with Expertise in Innovative Product Launches   NEW YORK – May 26, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and…

Anavex Life Sciences Reports Fiscal 2021 Second Quarter Financial Results And Business Outlook

Anavex Life Sciences Reports Fiscal 2021 Second Quarter Financial Results And Business Outlook  Conference Call and Webcast Today at 4:30 p.m. ET   NEW YORK – May 13, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including…

Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit

Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit  NEW YORK – May 7, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous…

Anavex Life Sciences to Announce Fiscal 2021 Second Quarter Financial Results and Business Outlook on Thursday, May 13, 2021

Anavex Life Sciences to Announce Fiscal 2021 Second Quarter Financial Results and Business Outlook on Thursday, May 13, 2021 Conference Call and Webcast To be Held Thursday, May 13, 2021 4:30 pm Eastern Time   NEW YORK – May 6, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical…

Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President for Nonclinical Development

Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President for Nonclinical Development   NEW YORK – May 05, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and…